← All trials
NCT02011958
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2014
- Primary completion
- Aug 1, 2016
- Completion date
- Apr 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 132
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Drugs for Neglected Diseases InitiativeLead sponsor
- University of GondarOverall official - principal investigator
- Addis Ababa UniversityCollaborator
- Institute of Tropical Medicine, BelgiumCollaborator
- Slotervaart HospitalCollaborator
- University of LondonCollaborator
- University of GondarCollaborator
- Medecins Sans FrontieresCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.